TAK788-3001
06 Dec 2021
TAK788-3001
NCT04129502
A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Millennium Pharmaceuticals, Inc
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2020-01-06 |
Anticipated End Date | 2022-06-30 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs